SNGX SOLIGENIX, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 812796 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-85.8%
TTM net income YoY-34.6%
TTM EPS YoY60.7%
Revenue 3-yr CAGR-47.5%
Net income 3-yr CAGR—
Margins
Gross margin0.0%
Operating margin-7,907.7%
Net margin-6,925.1%
FCF margin—
EBITDA margin—
Returns
ROE-249.0%
ROA-88.1%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets54.1%
Debt / equity0.00x
Current ratio1.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio1.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | $119,371 |
| Cost of revenue | — | $119,371 |
| Gross profit | — | $0 |
| R&D expense | $7.49M | $5.22M |
| SG&A expense | $4.36M | $4.22M |
| Operating income | -$11.85M | -$9.44M |
| Pretax income | -$11.59M | -$8.68M |
| Income tax | -$506,615 | -$409,114 |
| Net income | -$11.08M | -$8.27M |
| EPS (basic) | -2.14 | -4.98 |
| EPS (diluted) | -2.14 | -4.98 |
| Weighted avg. shares (diluted) | 5.19M | 1.66M |
| Balance sheet | ||
| Cash & equivalents | $7.94M | $7.82M |
| Current assets | $8.85M | $8.83M |
| PP&E, net | $8,772 | $6,113 |
| Total assets | $9.24M | $8.97M |
| Current liabilities | $3.70M | $4.85M |
| Long-term debt | — | $0 |
| Total debt | — | $0 |
| Total liabilities | $3.94M | $4.85M |
| Shareholders' equity | $5.29M | $4.12M |
| Net debt | — | -$7.82M |
| Shares outstanding | 10.09M | 2.51M |
| Cash flow statement | ||
| Operating cash flow | -$10.27M | -$8.40M |
| Capital expenditure | $5,883 | — |
| Free cash flow | -$10.27M | — |
| Investing cash flow | -$5,883 | — |
| Financing cash flow | $10.39M | $7.76M |
| Stock-based compensation | $587,583 | $329,815 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.